Phase 4 study of Panitumumab in advanced colorectal cancer

Intervention1: Panitumumab: Panitumumab is a fully human, IgG2 monoclonal antibody against epidernal growth factor recepto (EGFR). It is currently licensed in various regions across the world including United States, European Union, Canada, Australia and Japan, as first-, second- or third-line treatment of wild-type KRAS metastatic colorectal cancer.
Panitumumab will be administered as 6 mg/kg intravenous infusion every 14 days until disease progression, intolerability, withdrawal of consent, or death.
Control Intervention1: Nil: Nil
Primary outcome(s): Safety and tolerability of panitumumab in the labelled dose in 50 subjects with previously treated wild-type KRAS and wild-type NRAS metastatic colorectal cancerTimepoint: Laboratory evaluations every 4 weeks, Physical examination every 2 weeks, adverse event monitoring through out the study duration.